Abstract 46P
Background
The drug resistance against chemotherapy and high metastasis rate in triple-negative breast cancer reduce the success of breast cancer treatment. Glutathione S-transferase P1 enzyme (GSTP1) expression increases in cancer cell lines and leads to the development of drug resistance against chemotherapy. The antioxidant chlorophyllin is shown to have an inhibitory effect on GSTP1. The purpose of this study is to investigate the effects of GSTP1 inhibitor chlorophyllin and/or its coadministration with anticancer drug docetaxel on metastatic processes in vitro/in vivo in the 4T1 triple-negative breast cancer cell line and animal model.
Methods
Cell viability, cell cycle, and cell migration were investigated by MTT test, flow cytometry, and wound closure assay, respectively. Matrix metalloproteinase 9 (MMP-9) expression, causing invasion, was determined by Western Blot in the 4T1 cell line and tissue samples. Further, total gelatinase enzyme activity was also detected by gelatin degradation assay. Total GST enzyme activity and glutathione levels of tissue were investigated by colorimetric methods. Micrometastatic foci in liver tissue sections were evaluated by histochemistry.
Results
As a result, coadministration of chlorophyllin and docetaxel significantly inhibited cell migration in vitro. Chlorophyllin significantly reduced the expression of MMP-9 in the tissue samples, and this effect was higher when it is coadministered with docetaxel. In coadministration, a significant decrease was observed in the total gelatinase activity in vivo. It was also determined that chlorophyllin increased in vivo total glutathione levels and decreased GST enzyme activity. Finally, the micrometastases in the liver were reduced by coadministration.
Conclusions
Our results suggest that the coadministration of chlorophyllin and docetaxel may have a potential role in the control of metastatic processes by suppressing cell migration and invasion which is mainly characterized by gelatinase enzyme expression & activity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Hacettepe University Scientific Research Projects Coordination Unit.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Cold atmospheric plasma-activated fluids as a potential new intravesical agent for the treatment of bladder cancer
Presenter: Maria Filomena Botelho
Session: Poster session 09
90P - Discovery of CMPD1 as a tumor-specific cytotoxic microtubule inhibitor
Presenter: Mamoru Takada
Session: Poster session 09
91P - Erythroid precursor-differentiated myeloid cells promote pulmonary metastasis in hepatocellular carcinoma
Presenter: Wei-hang Zhu
Session: Poster session 09
92P - Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs
Presenter: Hsing-Pang Hsieh
Session: Poster session 09
93P - Transcriptome changes of immune cells across chemotherapy of triple-negative breast cancer
Presenter: Tatiana Gerashchenko
Session: Poster session 09
509P - Spatial analysis of tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Presenter: Markus Kleinberger
Session: Poster session 09
510P - CD47 regulates cellular and metabolic plasticity in glioblastoma
Presenter: Ruhi Polara
Session: Poster session 09
511P - Immunodisruptive conditions and glioma diagnosis: 24-year retrospective study of an under-recognized scenario
Presenter: Santiago Cabezas-Camarero
Session: Poster session 09
512P - Heterozygous germline Fanconi anemia-related gene mutations increase susceptibility to central nervous system germ cell tumors
Presenter: Guangyu Wang
Session: Poster session 09
513P - Cyclin pathway in oligodendrogliomas IDH mut and 1p/19q codeleted
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 09